Display Settings:

Format

Send to:

Choose Destination
    Target Oncol. 2009 Dec;4(4):253-4. Epub 2009 Nov 13.

    Sunitinib paves the way for targeted therapies in neuroendocrine tumors.

    Source

    Department of Medical Oncology and Gastroenterology, Beaujon University Hospital, Clichy, France. eric.raymond@bjn.aphp.fr

    Abstract

    Sunitinib demonstrating efficacy in pancreatic islet cell carcinomas will pave the way for further trials in other neuroendocrine tumor types such as carcinoid, poorly differentiated neuroendocrine disease, and several other endocrine tumors that are dependent on VEGF/VEGFR for angiogenesis. In addition, other drugs with distinct mechanisms of action, such as mTOR inhibitors, currently investigated in phase III trials, may also supply novel options in those diseases to control tumor growth and metastasis.

    PMID:
    19911111
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Springer

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk